FDA Approved: DEPAKOTE — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Depakote (divalproex sodium) submitted by AbbVie, resulting in labeling changes for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Epilepsy
• Migraine

Drugs mentioned

• DEPAKOTE (DIVALPROEX SODIUM)

Snippet

SUPPL AP for DEPAKOTE (DIVALPROEX SODIUM)